Citigroup upgraded Hims & Hers Health (NYSE: HIMS) from Sell to Neutral on March 10, 2026, with an analyst price forecast implying 27.68% upside. The change is a positive analyst-driven reassessment of the stock rather than company-released results and is likely to produce a modest, stock-specific move rather than broader sector impact.
Citigroup upgraded Hims & Hers Health (NYSE: HIMS) from Sell to Neutral on March 10, 2026, with an analyst price forecast implying 27.68% upside. The change is a positive analyst-driven reassessment of the stock rather than company-released results and is likely to produce a modest, stock-specific move rather than broader sector impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
